BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 19, 2004
 |  BioCentury  |  Product Development

New stopwatch for PPAR developers

FDA's new guidance concerning the timing of two-year carcinogenicity studies for peroxisome proliferation activated receptor (PPAR) agonists could re-level the playing field, delaying development of compounds in mid-stage clinical development without holding up compounds in early clinical development.

As a result of the guidance, partners Ligand Pharmaceuticals Inc. and Eli Lilly and Co. last week announced that the development timeline of naveglitazar (LY818) would be delayed 18-24 months. The guidance states that clinical studies of PPAR agonists lasting longer than six months are not permissible until two-year rodent carcinogenicity studies are completed and submitted.

According to LGND (San Diego, Calif.), FDA's requirement for two-year rodent carcinogenicity studies is not new - the...

Read the full 555 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >